292 related articles for article (PubMed ID: 34397863)
1. Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis.
Kong Y; Hong L; Xu X; Xu J
Medicine (Baltimore); 2021 Aug; 100(31):e26862. PubMed ID: 34397863
[TBL] [Abstract][Full Text] [Related]
2. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Shan F; Zhang B; Sun L; Xie L; Shen M; Ruan S
Biomed Res Int; 2018; 2018():5839081. PubMed ID: 29998136
[TBL] [Abstract][Full Text] [Related]
7. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Hu X; Pu K; Feng X; Wen S; Fu X; Guo C; He W
PLoS One; 2016; 11(3):e0149247. PubMed ID: 26954503
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Kasai T; Mori K; Nakamura Y; Seki N; Ichikawa Y; Saito H; Kondo T; Nishikawa K; Otsu S; Bessho A; Tanaka H; Yamaguchi H; Kaburagi T; Imai H; Mori K; Ohtake J; Okamoto H
Cancer Med; 2023 Jul; 12(14):14988-14999. PubMed ID: 37226421
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF;
Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482
[TBL] [Abstract][Full Text] [Related]
11. Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Hashemi-Sadraei N; Pennell NA
Curr Treat Options Oncol; 2012 Dec; 13(4):478-90. PubMed ID: 22972369
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
Yoshida H; Kim YH; Sakamori Y; Nagai H; Ozasa H; Kaneda T; Yoshioka H; Nakagawa H; Tomii K; Okada A; Yoshimura K; Hirabayashi M; Hirai T
Anticancer Res; 2020 May; 40(5):2981-2987. PubMed ID: 32366452
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
Ramalingam SS; Dahlberg SE; Belani CP; Saltzman JN; Pennell NA; Nambudiri GS; McCann JC; Winegarden JD; Kassem MA; Mohamed MK; Rothman JM; Lyss AP; Horn L; Stinchcombe TE; Schiller JH
J Clin Oncol; 2019 Sep; 37(26):2360-2367. PubMed ID: 31361535
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ
J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
[TBL] [Abstract][Full Text] [Related]
18. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A
Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722
[TBL] [Abstract][Full Text] [Related]
19. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
20. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]